A Phase 2 interventional study of Donepezil and Solifenacin in Dementia of Alzheimer's Type, sponsored by Chase Pharmaceuticals Corporation, an affiliate of Allergan plc. Completed at 4 sites in United States. Open to participants aged 50 Years to 89 Years. Per ClinicalTrials.gov, last updated 2019-03-05.
Sponsored by Chase Pharmaceuticals Corporation, an affiliate of Allergan plc (part of AbbVie) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing donepezil in Dementia — none open to participants now, none under way, none of them phase 3. Donepezil · Dementia.
Among the 26 studies testing donepezil in Dementia, this one is the 22nd largest by enrollment of the 24 interventional ones that give a count, is one of 4 that started in 2015, is one of 5 in phase 2, and was the 24th registered.
2,375 studies on the registry are indexed under Dementia; 573 are open to participants now.
Browse Dementia studies →None of the 26 studies testing donepezil in Dementia is open now. The open studies under Dementia, anywhere →
Donepezil: first FDA approval 1996 (ARICEPT). What it is approved for, and how studies give it, is on its page →
Of the 383 Dementia studies recruiting now, 244 (64%) set no upper age limit and 25 (7%) stop at 75 or younger; 16 take children under 18; 164 take healthy volunteers.
This study: 50 Years to 89 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 4 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 90 across 1,760 interventional studies indexed under Dementia.
Median enrollment 151 across the 24 interventional studies. Of the 24 that completed or were terminated, 10 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 26 have an industry lead sponsor. The 10 most frequent:
This study is registered under Chase Pharmaceuticals Corporation, an affiliate of Allergan plc, one of the names counted as AbbVie. Under that name alone:
Chase Pharmaceuticals Corporation, an affiliate of Allergan plc is the lead sponsor of 4 studies on the registry; none are open to participants now.
AbbVie has 6 studies filed under Dementia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing donepezil in Dementia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase II, ascending dose study of CPC-201 in patients with dementia of Alzheimer's type to determine the optimal dose titration schedule.
This is a Phase II, ascending dose study of CPC-201 in patients with dementia of Alzheimer's type to determine the optimal dose titration schedule. The study involves a step wise cohort design in two different patient populations: Group 1 will comprise of patients who have been treated with low dose of CPC-201(5 or 10 mg/day) (given once daily) for at least 4 weeks just prior to Day1. Group 2 will consist of patients who have never been treated with CPC-201 before or who have not received any other AChEI for the past 6 months.
In this study, CPC-201 dose will be increased at weekly intervals, in accordance with the schedules given below, to its first intolerable dose (FID) or maximum allowed dose (MAD) of 60 mg/day (40mg/day for Cohort 3c) together with solifenacin 15 mg/day.
Cohort 1 1st week: 20mg 2nd week: 30mg 3rd week: 40mg 4th week: 50mg 5th week: 60mg Cohort 2* 1st week: 20mg 2nd week: 40mg 3rd week: 60mg Cohort 1b 1st - 2nd week: 10mg 3rd week: 20mg 4th week: 30mg 5th week: 40mg 6th week: 50mg 7th week: 60mg Cohort 3c* 1st week: 10mg 2nd week: 15mg 3rd week: 20mg 4th week: 25mg 5th week: 30mg 6th week: 35mg 7th week: 40mg
*: The dose titration schedule of Cohort 2 and 3 may be altered based on Cohort 1 result.
Patients will be enrolled in Cohort 2 only when patients enrolled in Cohort 1 have safely completed titration. Similary, patients will be enrolled in Cohort 3, only when patients enrolled in Cohort 2 have safely completed titration.
Patients reaching their FID or having completed one week treatment with donepezil 40mg/day, have two options.
Option 1: Patient will be allowed to immediately enter a long term extension at their Maximum tolerated dose (MTD) or MAD.
Option 2: Patients may choose not to enter the long term extension, in which case the Investigator will decide whether the patient should discontinue high dose of donepezil without down-titration, or whether donepezil should be downtitrated to their own standard of donepezil dose.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Meeting the diagnosis of probable AD consistent with:
Exclusion Criteria:
Renal and hepatic dysfunction with:
findings of:
Patients treated with the following medications within 8 weeks of screening
Other medications are acceptable, at the investigators discretion, if dosage is held stable for at least 4 weeks prior to screening and throughout the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Donepezil 20mg/day upward dose titration of 10mg at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) of 60mg/day with solifenacin 15 or 20mg/day.
Drug: Donepezil · Drug: Solifenacin
Donepezil 20mg/day upward dose titration of 20mg at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) of 60mg/day with solifenacin 15 or 20mg/day.
Drug: Donepezil · Drug: Solifenacin
Donepezil 10mg/day upward dose titration of 10mg at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) of 60mg/day with solifenacin 15 or 20mg/day.
Drug: Donepezil · Drug: Solifenacin
Donepezil 10mg/day upward dose titration of 5mg at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) of 40mg/day with solifenacin 15mg/day.
Drug: Donepezil · Drug: Solifenacin
Donepezil dose increased at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) together with solifenacin.
Donepezil dose increased at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) together with solifenacin.
Number of Participants Who Reached the Maximum Allowed Dose (MAD) in Their Respective Cohort
Of the four cohorts with different dosing schedules for CPC-201, the cohort with the greatest proportion of participants to reach the donepezil MAD was determined to be the optimal administration regimen.
Time frame: 1-7 weeks
Number of Participants With TEAEs Leading to Study Drug Discontinuation
Number of subjects who experienced any treatment-emergent adverse events (TEAEs) leading to study drug discontinuation
Time frame: 1-7 weeks
| Milestone | Cohort 1 | Cohort 2 | Cohort 1b | Cohort 3c |
|---|---|---|---|---|
| Started | 8 | 1 | 6 | 13 |
| Completed | 7 | 1 | 5 | 12 |
| Not completed | 1 | 0 | 1 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 | 1 | 0 |
Of the four cohorts with different dosing schedules for CPC-201, the cohort with the greatest proportion of participants to reach the donepezil MAD was determined to be the optimal administration regimen.
| Participants | Cohort 1 | Cohort 2 | Cohort 1b | Cohort 3c |
|---|---|---|---|---|
| Number of Participants Who Reached the Maximum Allowed Dose (MAD) in Their Respective Cohort | 2 | 0 | 1 | 6 |
Number of subjects who experienced any treatment-emergent adverse events (TEAEs) leading to study drug discontinuation
| Participants | Cohort 1 | Cohort 2 | Cohort 1b | Cohort 3c |
|---|---|---|---|---|
| Number of Participants With TEAEs Leading to Study Drug Discontinuation | 2 | 0 | 1 | 4 |
Collected over Adverse events were collected until week 7.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 | 0/8 (0%) | 1/8 (12.5%) | 6/8 (75%) |
| Cohort 2 | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Cohort 1b | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Cohort 3c | 1/13 (7.7%) | 1/13 (7.7%) | 12/13 (92.3%) |
| Event | Cohort 1 | Cohort 2 | Cohort 1b | Cohort 3c |
|---|---|---|---|---|
| SyncopeNervous system disorders | 1/8 | 0/1 | 0/6 | 0/13 |
| Duodenal ulcer haemorrhageGastrointestinal disorders | 0/8 | 0/1 | 0/6 | 1/13 |
| Cardio-respiratory arrestCardiac disorders | 0/8 | 0/1 | 0/6 | 1/13 |
| Event | Cohort 1 | Cohort 2 | Cohort 1b | Cohort 3c |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 4/8 | 1/1 | 2/6 | 2/13 |
| VomitingGastrointestinal disorders | 4/8 | 0/1 | 1/6 | 2/13 |
| DizzinessNervous system disorders | 2/8 | 0/1 | 2/6 | 1/13 |
| Abdominal pain upperGastrointestinal disorders | 2/8 | 0/1 | 0/6 | 0/13 |
| HeadacheNervous system disorders | 2/8 | 0/1 | 0/6 | 0/13 |
| ConstipationGastrointestinal disorders | 1/8 | 0/1 | 0/6 | 3/13 |
| Blood pressure systolic increasedInvestigations | 0/8 | 0/1 | 0/6 | 3/13 |
| Decreased appetiteMetabolism and nutrition disorders | 0/8 | 0/1 | 1/6 | 3/13 |
| TremorNervous system disorders | 1/8 | 0/1 | 1/6 | 1/13 |
| AnxietyPsychiatric disorders | 0/8 | 0/1 | 1/6 | 1/13 |
| Age, Continuous(Years) | Cohort 1 | Cohort 2 | Cohort 1b | Cohort 3c | Total |
|---|---|---|---|---|---|
| Mean | 72 ± 10.6 | 74 | 75.5 ± 6.9 | 73 ± 8.4 | 73.3 ± 8.8 |
| Sex: Female, Male(Participants) | Cohort 1 | Cohort 2 | Cohort 1b | Cohort 3c | Total |
|---|---|---|---|---|---|
| Female | 6 | 0 | 3 | 5 | 14 |
| Male | 2 | 1 | 3 | 8 | 14 |
| Race/Ethnicity, Customized(Participants) | Cohort 1 | Cohort 2 | Cohort 1b | Cohort 3c | Total |
|---|---|---|---|---|---|
| White | 8 | 1 | 5 | 11 | 25 |
| Black or African- American | 0 | 0 | 1 | 2 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2015 to primary completion in Sep 2017, 23 months.
Results were first posted in Mar 2019, 1 year 5 months after primary completion.
Of 41 industry-sponsored phase 2 interventional studies under Dementia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 23 months is below that.
Counting every sponsor, half of 83 studies reached it within 38 months; a quarter within 23 and three quarters within 61.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Donepezil · Solifenacin
Chase Pharmaceuticals Corporation, an affiliate of Allergan plc →